TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02150356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aleurone
Description: Diet based in aleurone-enriched products for a period of 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Diet based on refined cereal products for a period of 8 weeks.
Study: NCT00315146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise training to maximize muscle power

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise training to maximize muscle power

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT04362332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Sulfate
Description: cluster randomized
Study: NCT02959463

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo hemithoracic radiation therapy
Study: NCT00630643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NI-0401 (anti-CD3 mAB)
Description: 0.05 mg up to 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04362332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: cluster randomized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: cluster randomized

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard supportive care
Description: cluster randomized
Study: NCT03992651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements of capnia and tissue oxygenation by optical transcutaneous sensors
Description: Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
Study: NCT01754376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Intravenous therapy given every 8 hours for up to 14 doses per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Tablets given twice daily.
Study: NCT00458445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a material that may look similar to SPD465, however, contains no active drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a material that may look similar to SPD465, however, contains no active drug.
Study: NCT00418067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor
Description: Zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: Sirolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte
Description: Paclitaxel-eluting stent
Study: NCT00051831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Will be administered as one 200-mg capsule orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide
Description: Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Will be administered as one 100-mg capsule orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir
Description: Will be administered as five hard gel capsules orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Will be administered as one 300-mg tablet orally daily
Study: NCT04397640

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sonovue
Description: Contrast myocardial echocardiography with sulphur hexafluoride microbubbles Sonovue (Bracco, Milan, Italy) injection and using the time-intensity curves profile to evaluate the myocardial microcirculation.
Study: NCT03127306

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Polish version of BPS
Description: Validation of Polish Version of BPS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Polish version of BPS
Description: Validation of Polish Version of BPS.
Study: NCT04311944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early fast-track care
Description: Participants will be eligible for fast-track care at 8 weeks if their HIV-1 RNA is \<200 copies/mL and they meet other eligibility criteria. If HIV-1 RNA is 200 copies/mL or higher at 8 weeks, then it will be repeated at 12 weeks, and those with HIV-1 RNA \<200 copies will then be eligible for fast-track care, if they meet other eligibility criteria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (deferred fast-track) care
Description: Participants will be eligible for fast-track care at 24 weeks, if their HIV-1 RNA is \<200 copies.mL, and they meet other eligibility criteria.
Study: NCT03237299

Intervention type: OTHER
Intervention: Collection of data
Description: Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.

Intervention type: OTHER
Intervention: No collection of data
Description: The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
Study: NCT02985398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD403 (Eptinezumab)
Study: NCT02324231

Intervention type: OTHER
Group type: OTHER
Intervention: 39.0°C temperature limit defining fever
Description: Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.

Intervention type: OTHER
Group type: OTHER
Intervention: 38.5°C temperature limit defining fever
Description: Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
Study: NCT01247844

Intervention type: DEVICE
Group type: OTHER
Intervention: Shang Ring
Description: The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing

Intervention type: DEVICE
Group type: OTHER
Intervention: Shang Ring
Description: The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing

Intervention type: DEVICE
Group type: OTHER
Intervention: Shang Ring
Description: The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
Study: NCT03705871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Differential Expansion
Description: Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fan-Fype Expander
Description: Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
Study: NCT01835535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIVUS
Study: NCT05458037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speed of tenaculum application
Description: Fast or slow closure of the tenaculum for application to the uterine cervix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Speed of tenaculum application
Description: Fast or slow closure of the tenaculum for application to the uterine cervix
Study: NCT02994290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
Study: NCT01461980

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rLP2086 + MCV4 + Tdap
Description: At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MCV4 + Tdap + saline
Description: At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: rLP2086 + saline
Description: At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
Study: NCT02994290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Postpartum HPV Immunization Quality Improvement Program
Description: The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Postpartum HPV Immunization Quality Improvement Program
Description: The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed.
Study: NCT03911180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proximal femoral nail with straight parallel blade
Description: Petrochanteric fixation with Heracles proximal femoral nail
Study: NCT00556699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Escalating intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: Escalating intravenous repeating dose
Study: NCT03947398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLIMP balloon
Description: Using BLIMP balloon to cross lesion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low profile balloon
Description: using low profile balloon to cross lesion
Study: NCT01622660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
Study: NCT03303417

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: MRI Scan
Description: Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiwifruit
Description: Kiwifruit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: calorie-matched sugar drink
Description: calorie-matched sugar drink
Study: NCT00071539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-38
Description: Recombinant chimeric protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP38
Description: recombinant chimeric protein
Study: NCT00818220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed umbilical cord clamping
Description: at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: The umbilical cord is cut within 10 seconds after birth
Study: NCT04197258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support
Description: The intervention studied is the psycho-social support by a peer-helper to the patients and their main informal caregiver during the return home following a stay in rehabilitation center for a stroke.~Peer support intervention will be based on evidence, Bandura's social learning and social support theory, and the results of our ongoing study of the needs of patients and their caregivers as a result of returning home (Stroke69). It will include a meeting before the discharge and a regular follow-up for 6 months (face-to-face meetings, virtual or by phone), adapted to the needs of the patient and his caregiver, taking into account the social environment and in connection with the devices existing sanitary and social.
Study: NCT01370239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3S193
Description: Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
Study: NCT03460990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659/TEZ/IVA
Description: Participants received VX-659/TEZ/IVA orally once daily in the morning.
Study: NCT02024529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Description: 4 mL Injection of Placebo
Study: NCT00723398

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lovaza 4gm oral
Description: Dietary supplement; Take 4 mg oral capsules daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 Mg Oral Tablet
Description: 60 mg orally every day for two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene 30 Mg Oral Tablet
Description: 30 mg orally daily for two years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza 4gm & Raloxifene 30mg
Description: Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
Study: NCT02503709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK Inhibitor AT7519
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03460990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TEZ/IVA
Description: Participants received TEZ/IVA orally once daily in the morning.
Study: NCT00191906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine Hydrochloride
Description: Atomoxetine, 1.2 mg/kg/day, by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine Hydrochloride
Description: Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
Study: NCT03460990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Participants received IVA orally once daily in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants received placebo matched TEZ/IVA orally once daily in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
Study: NCT04067154

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ALPE
Description: Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
Study: NCT03098693

Intervention type: BEHAVIORAL
Intervention: HIV Self-Testing
Description: Access to home-based HIV self-testing kits for stable couples.

Intervention type: BEHAVIORAL
Intervention: Immediate Access to ART for HIV infected couple members
Description: Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
Study: NCT00191906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo, every day (QD), by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo, every day (QD), by mouth (PO)
Study: NCT03098693

Intervention type: BEHAVIORAL
Intervention: Access to PrEP for HIV uninfected couple members
Description: Access to PrEP for HIV uninfected couple members.
Study: NCT03368248

Intervention type: OTHER
Intervention: Survey
Description: A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
Study: NCT01604915

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Caudal block
Description: After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
Study: NCT03533101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
Study: NCT02112344

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT